Evidence map›Paper›PMID 40980649›Full record

ArticleKidney international reports2025

Efficacy of Acthar gel and Tacrolimus in DNA-JB9 Positive Fibrillary Glomerulopathy.

James A Tumlin, Amber Podoll, Nelson Kopyt, Brad Rovin, Richard Lafayette, Andrew Bomback, Richard Glassock, Jeremy Whitson, Adam Press, Gerald B Appel

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Kidney international reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

James A TumlinNephroNet Clinical Trials Group, Emory University School of Medicine, Department of Nephrology, Lawrenceville, Georgia, USA.
Amber PodollHealth and Kidney Disease, Anschutz Medical Campus School of Medicine, University of Colorado, Aurora, Colorado, USA.
Nelson KopytKidney Care Specialists, Jefferson Health, Allentown, Pennsylvania, USA.
Brad RovinInternal Medicine-Nephrology, Ohio State University, Columbus, Ohio, USA.
Richard LafayetteNephrology, Stanford University, Stanford, California, USA.
Andrew BombackDivision of Nephrology, Vagelos College of Physicians and Surgeons, Columbia University, New York, New York, USA.
Richard GlassockDepartment of Medicine, University of California at Los Angeles, Los Angeles, California, USA.
Jeremy WhitsonNephroNet Clinical Trials Group, Emory University School of Medicine, Department of Nephrology, Lawrenceville, Georgia, USA.
Adam PressNephroNet Clinical Trials Group, Emory University School of Medicine, Department of Nephrology, Lawrenceville, Georgia, USA.
Gerald B AppelDivision of Nephrology, Vagelos College of Physicians and Surgeons, Columbia University, New York, New York, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Fibrillary glomerulopathy (FGN) is a rare glomerular disease characterized by the deposition of randomly arranged fibrils that results in proteinuria and end-stage renal disease (ESRD) in up to 50% of patients within 2 years. The FACT trial is a prospective, randomized, open-labeled study of patients with biopsy-proven, DNA-JB9 positive FGN comparing the safety and efficacy of repository corticotropin (ACTH) injection, Acthar gel alone or in combination with tacrolimus on proteinuria and change in estimated glomerular filtration rate (eGFR). Methods: Patients ( Results: A total of 34 patients completing 1 year of therapy were analyzed. In the ACTH-alone group (19 patients), UPCR decreased from a mean of 6.21 ± 0.8 g/g at baseline to 2.92 ± 0.90 g/g ( Conclusion: Repository ACTH (Acthar gel) significantly reduced UPCR at 6 and 12 months. The addition of tacrolimus was not additive with ACTH in reducing proteinuria or stabilization of eGFR. Acthar gel is an effective antiproteinuric therapy for DNA-JB9 positive FGN.

Indexed as

DNA-JB9FACT trialfibrillary glomerulopathy

Identifiers

PMID40980649
PMCPMC12446950

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.